May 6, 2021 – The U.S. FDA has approved a new single-dose option for Injectafer® (ferric carboxymaltose
injection), manufactured by Daiichi Sankyo. Injectafer is indicated to treat iron deficiency
May 5, 2021 – The U.S. FDA has approved a new indication for Keytruda® (pembrolizumab), manufactured
by Merck. Keytruda is now indicated for use in combination with trastuzumab and
May 4, 2021 – Hospira, Inc., a subsidiary of Pfizer, has voluntarily recalled one lot of 0.5% Bupivacaine
Hydrochloride (HCl) Injection, USP 30mL, and one lot of 1% Lidocaine HCl Injection
May 1, 2021 – The U.S. FDA has approved a new indication for Ferriprox® (deferiprone), manufactured by
Chiesi USA, to treat transfusional iron overload due to sickle cell disease (SCD) or other
April 30, 2021 – The U.S. FDA has approved KloxxadoTM (naloxone hydrochloride) nasal spray,
manufactured by Hikma Pharmaceuticals, for the emergency treatment of known
April 30, 2021 – Acella Pharmaceuticals has voluntarily recalled more than 30 lots of 15mg, 30mg, 60mg,
90mg, and 120mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine
April 30, 2021 – The U.S. FDA has approved a new indication for Farxiga® (dapagliflozin), manufactured by
AstraZeneca. The drug is now indicated for use in adults who have chronic kidney disease
April 28, 2021 – The U.S. FDA has approved a new indication for NatrobaTM (spinosad) topical solution
0.9%, manufactured by ParaPRO, to treat scabies infestations in patients who are at